ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Tracy I. George, MD, Chief Medical Officer

Patient Report

Patient Age/Gender: 21 years Male

Specimen Collected: 22-Jun-21 17:33

Rheumatoid Arthritis Pan	**|Received: 22-Jun-21 17:44**		**Report/Verified: 22-Jun-21 18:12**
Procedure	**Result**	**Units**	**Reference Interval**
Carbamylated Protein Antibody,IgG	20 H i1	Units	0-19

Rheumatoid Arthritis Pan	**|Received: 22-Jun-21 17:44**		**Report/Verified: 23-Jun-21 11:02**
Procedure	**Result**	**Units**	**Reference Interval**
Cyclic Citrullinated Peptide Ab,IgG	20 H i2	Units	0-19

Rheumatoid Arthritis Pan	**|Received: 22-Jun-21 17:44**		**Report/Verified: 23-Jun-21 12:48**
Procedure	**Result**	**Units**	**Reference Interval**
Rheumatoid Factor	15 H	IU/mL	0-14

Test Information

i1: Carbamylated Protein Antibody, IgG

INTERPRETIVE INFORMATION: Carbamylated Protein (CarP) Ab, IgG

Anti-carbamylated protein (anti-CarP) IgG antibodies are present in about 34-53 percent of patients with RA, have specificities of greater than 90 percent and can occur in RA patients seronegative for both rheumatoid factor and anti-CCP. These autoantibodies may be present in the preclinical phase of disease, are associated with future RA development, and may predict radiographic joint destruction. Patients with weak positive results should be monitored and testing repeated.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i2: Cyclic Citrullinated Peptide Ab, IgG

INTERPRETIVE INFORMATION: Cyclic Citrullinated Peptide Antibody, IgG

19 Units or less ..... Negative
20-39 Units ..... Weak Positive
40-59 Units ..... Moderate Positive
60 Units or greater ..... Strong Positive

Anti-cyclic citrullinated peptide (anti-CCP), IgG antibodies are present in about 69-83 percent of patients with rheumatoid arthritis (RA) and have specificities of 93-95 percent. These autoantibodies may be present in the preclinical phase of disease, are associated with future RA development, and may predict radiographic joint destruction. Patients with weak positive results should be monitored and testing repeated.

Unless otherwise indicated, testing performed at:
ARUP Laboratories
500 Chipeta Way, Salt Lake City, UT 84108
Laboratory Director: Tracy I. George, MD

ARUP Accession: 21-173-900278
Report Request ID: 15025139
Printed: 23-Jun-21 15:04